Puma Biotechnology
PBYI
141 hedge funds and large institutions have $717M invested in Puma Biotechnology in 2018 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 45 increasing their positions, 48 reducing their positions, and 43 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
6% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 48
1.83% less ownership
Funds ownership: 94.12% → 92.29% (-1.8%)
10% less funds holding
Funds holding: 156 → 141 (-15)
30% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 43
48% less call options, than puts
Call options by funds: $5.87M | Put options by funds: $11.2M
56% less capital invested
Capital invested by funds: $1.64B → $717M (-$923M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$43.2M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$41.4M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$40.3M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$34.8M |
| 5 |
Millennium Management
New York
|
+$32.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$106M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$84.9M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$52.8M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$28.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$24.3M |
PBYI Hedge Fund Activity: Q4 2018 in Review
141 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q4 2018, worth a combined $717M — down 56% from $1.64B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of PBYI and 30 opened new positions — a net loss of 13 holders — while 48 trimmed existing stakes and 45 added.
The largest buyer was Federated Hermes, adding an estimated $43.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $106M sold.
- 141 institutional investors held Puma Biotechnology (PBYI) as of Q4 2018, down from 156 in Q3 2018.
- Funds reported $717M of Puma Biotechnology stock for Q4 2018, down 56% quarter-over-quarter.
- 30 funds opened new Puma Biotechnology positions in Q4 2018 and 43 closed out, a net change of -13 holders.
- The largest Puma Biotechnology buyer in Q4 2018 was Federated Hermes, an estimated $43.2M added.
- The largest Puma Biotechnology seller in Q4 2018 was Consonance Capital Management, an estimated $106M sold.
Based on aggregated 13F filings for Q4 2018.